Is Eli Lilly Stock a Buy After Gaining 10% in 1 Month?

It's been a volatile year for Eli Lilly (NYSE: LLY), with the pharmaceutical giant experiencing some setbacks. However, the drugmaker has been on a roll over the past month, with several catalysts propelling the stock and resulting in a 10% gain during this period. It's seldom a good idea to make investment decisions based on a single month of strong performance, but some ongoing developments with Eli Lilly are definitely worth a second look.Eli Lilly has established itself as a leader in the rapidly growing weight loss market, thanks to Zepbound, a medication administered subcutaneously. The company also remains a top player in the diabetes drug market thanks to Mounjaro, which is generating impressive quarterly sales. However, the company is looking to improve its already excellent lineup in these areas. Eli Lilly is developing orforglipron, an oral GLP-1 medicine for diabetes and weight management.Oral pills have certain advantages compared to subcutaneous injections. The former don't require autoinjector devices, which often come with strict storage and transportation requirements for manufacturers. Many patients also prefer pills, since they are less painful and more discreet.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool